Compare M&T Bank Corporation (MTB) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
M&T Bank Corporation vs TG Therapeutics Inc — how do they compare? M&T Bank Corporation trades at $237.67 (market cap $34.43B), while TG Therapeutics Inc trades at $54.77 (market cap $8.53B). The key difference: M&T Bank Corporation is far larger — about 4× TG Therapeutics Inc's market cap, and M&T Bank Corporation pays a 2.52% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| MTB | TGTX | |
|---|---|---|
Market Cap | $34.43B | $8.53B |
Sector | Financials | Health |
52-Week High | $254.09 | $59.06 |
52-Week Low | $178.63 | $26.94 |
Dividend Yield | 2.52% | — |
Enterprise Value | — | $8.74B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
M&T Bank (MTB) trades at $238.44, down 0.58% on the day, with a bullish technical signal from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $5.35 surpassing the $4.66 forecast. Revenue growth is steady, reaching $9.63 billion in 2025, and the net income margin is strong at 30.85%. A quarterly dividend of $1.50 per share was recently declared, payable in September 2026.
The outlook is positive, supported by earnings beats and a consensus price target of $261.62, implying nearly 10% upside. Key risks include a negative net cash flow of -$2.01 billion in 2025 and rising debt levels, while analyst sentiment is mixed with a 'Hold' consensus amid macroeconomic uncertainty.
TG Therapeutics (TGTX) trades at $55.74, down 0.44% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $64.00. The company reported strong revenue growth, with Q2 2026 revenue reaching $240 million and full-year 2026 guidance raised to approximately $950 million, though recent quarterly EPS results have missed expectations. News highlights include conference participation and institutional buying interest, supporting positive sentiment.
The outlook remains optimistic driven by Briumvi's commercial growth and pipeline catalysts, but risks include earnings volatility, competitive pressures, and reliance on a key product. Upside potential exists if execution meets raised guidance, making it a focus for growth-oriented investors despite near-term profit misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About M&T Bank Corporation
M&T Bank is one of the largest regional banks in the United States, with branches in New York, Pennsylvania, West Virginia, Virginia, Maryland, Delaware, and New Jersey. The bank was founded to serve manufacturing and trading businesses around the Erie Canal and is primarily focused on commercial real estate and commercial-related lending, with some retail operations also present.
Read more on MTB →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
